Wire · opportunities
United lands 'clearcut win' as Liquidia agrees to $380M settlement in Tyvaso patent ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 14 October 2026 · Fusion42 review
United Therapeutics won a patent infringement lawsuit against Liquidia Technologies related to the inhaled treprostinil drug Tyvaso, securing a $380 million settlement. Liquidia agreed to remove the PH-ILD indication from its rival drug Yutrepia and will only market it for pulmonary arterial hypertension.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 3 sources have reported it between 30 Sep 2026 and 14 Oct 2026.
◆ ◆ The Wire takeaway
You just lost a potential market segment in lung disease indication as Liquidia pulls PH-ILD from their label, making your patent enforcement a lever for market exclusivity in pulmonary arterial hypertension. Realign your regulatory focus and competitor analysis to capitalise on cleared growth paths and abandoned segments.
◆ Coverage
3 sources · first reported 30 Sep 2026 · latest 14 Oct 2026
◆ Related on Wire
◆ Topics